Protocols
17 protocol(s) meet the specified criteria
Disease Site: Liver
Protocol No.TitleStatus
04-RAD-507-ORCA Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma and Metastatic Disease to the Liver Open
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid TumorsOpen
COG-AHEP0731Treatment of Children with All Stages of HepatoblastomaOpen
D6410C00001A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and Palliative Radiation in Subjects with Solid TumorsOpen
GI15-225A pilot study of pembrolizumab in combination with Y90 radioembolization in patients with high risk hepatocellular carcinoma with preserved liver functionOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
LCCC1527Evaluation of the Chemotherapy Toxicity Risk Score for Treatment Decision in Elderly Patients with Advanced Solid CancerOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
LCCC1705Quality of life in unresectable malignant biliary obstruction after biliary decompressionOpen
LCCC1706Qualitative analysis of quality of life in unresectable malignant biliary obstruction after biliary decompressionOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
MCC17651Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.Open
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
TARGET-HCCA 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular CarcinomaOpen
TRT-001A Multi-center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA Followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard TherapyOpen
VEG116731A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid TumorsOpen